Philadelphia, Pennsylvania
Colorectal cancer clinical trials in Philadelphia, PA
48 colorectal cancer studies are recruiting participants at sites in Philadelphia as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Philadelphia at a glance
- 48 studies are recruiting at a site in Philadelphia.
- By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (11), Phase 2 (3), Phase 2/3 (1), Phase 3 (6), Phase 4 (2), No phase (2), Observational (7). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (36), university, hospital or other (12).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Philadelphia
Basic details from each study's public record (the 30 most recently updated of 48). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT05863195 · updated
Decision Counseling and Follow-up for Shield+ Patients
- Observational
- Ages 45 to 75
- All sexes
- Sponsor
- Guardant Health, Inc.
- Study site
- Jefferson Center
- Registry record
- NCT07620535 · updated
Shield Post-Approval Study Protocol
- Observational
- Ages 45 to 81
- All sexes
- Sponsor
- Guardant Health, Inc.
- Study site
- University of Pennsylvania
- Registry record
- NCT06880055 · updated
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kestrel Therapeutics, Inc.
- Study site
- Sidney Kimmel Cancer Center
- Registry record
- NCT07458347 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Univ of Pennsylvania, Abramson Cancer Center
- Registry record
- NCT07020221 · updated
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT07228832 · updated
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Jefferson Torresdale Hospital · Pennsylvania Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT05174169 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study sites
- Fox Chase Cancer Center · University of Pennsylvania
- Registry record
- NCT07213791 · updated
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- Fox Chase Cancer Center · Thomas Jefferson University
- Registry record
- NCT06662786 · updated
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Sydney Kimmel Cancer Center
- Registry record
- NCT06720987 · updated
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- Fox Chase Cancer Center · Thomas Jefferson University
- Registry record
- NCT06750094 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT07542704 · updated
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- University of Pennsylvania
- Registry record
- NCT03526835 · updated
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
- Early Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Fox Chase Cancer Center
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT07167446 · updated
The Cancer of the Pancreas Screening-5 CAPS5)Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Johns Hopkins University
- Study site
- University of Pennsylvania
- Registry record
- NCT02000089 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study sites
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization · University of Pennsylvania / Abramson Cancer Center
- Registry record
- NCT04657068 · updated
GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Thomas Jefferson University
- Study site
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Registry record
- NCT07417488 · updated
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Criterium, Inc.
- Study site
- Thomas Jefferson University - Sidney Kimmel Comprehensive Cancer Center
- Registry record
- NCT06992258 · updated
TCR1188-ABC Cells in KRAS-mutated Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- University of Pennsylvania
- Study site
- University of Pennsylvania
- Registry record
- NCT07594067 · updated
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275407
- Registry record
- NCT07023289 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- University of Pennsylvania, Perelman School of Medicine
- Registry record
- NCT05919264 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- Abramson Cancer Center of the University of Pennsylvania
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #98
- Registry record
- NCT05176483 · updated
DESTINY-PANTUMOUR04
- Observational
- Ages 18 to 130
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07124000 · updated
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07277270 · updated
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Hospital of the University of Pennsylvania
- Registry record
- NCT06445062 · updated
Prehabilitation in High-risk Oncologic Surgery
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Fox Chase Cancer Center
- Study site
- Fox Chase Cancer Center - Philadelphia
- Registry record
- NCT07638410 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EvolveImmune United, Inc
- Study site
- Thomas Jefferson University, Sidney Kimmel Cancer Center
- Registry record
- NCT07217171 · updated
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Guardant Health, Inc.
- Study site
- University of Pennsylvania
- Registry record
- NCT05059444 · updated
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Phase 1
- Ages 12 to 85
- All sexes
- Sponsor
- Inhibrx Biosciences, Inc
- Study sites
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research · University of Pennsylvania Abramson Cancer Center
- Registry record
- NCT03715933 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Ask about studies near Philadelphia
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Pennsylvania
All Pennsylvania locations
91 studies recruiting across 61 cities.
Pittsburgh
37 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections